oa SA Pharmaceutical Journal - Pulmonary arterial hypertension : an overview for pharmacists : review

Volume 78, Issue 2
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Pulmonary arterial hypertension (PAH) is a syndrome characterised by a progressive increase in pulmonary vascular resistance which leads to right ventricular overload and eventually to right ventricular failure and premature death. It is associated with several predisposing factors and causes which play a role in the choice of therapy, as well as the prognosis. The syndrome has recently been reclassified in order to assist with therapy choice. Initial signs and symptoms include unexplained breathlessness and fatigue. Until the identification of three pathological pathways, the prognosis was very poor, but based on these pathways, recent advances in therapy have significantly improved functional scores and symptoms. Early diagnosis and appropriate treatment play a significant role in the management of this syndrome.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error